Sohail Mulla

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Prevalence, Characteristics, and Publication of Discontinued Randomized Trials

Benjamin Kasenda, Erik von Elm, John J. You et al. · JAMA · 2014 · 430 citations · Full text

Public Health, Public Health Ethics, Clinical Epidemiology +16

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin et al. · The Lancet Oncology · 2021 · 373 citations

Medicine, Oncology, Pharmacotherapy +11

Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid

Elie A. Akl, Xin Sun, Jason W. Busse et al. · Journal of Clinical Epidemiology · 2011 · 179 citations

Public Health, Biostatistics, Experimental Design +10

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Shukui Qin, Zhenggang Ren, Yin‐Hsun Feng et al. · Liver Cancer · 2021 · 129 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +12